TRI 003: T 20 ADMINISTERED TO HIV+ ADULTS BY SQ INFUSION V SQ INJECTION
$21,006M01FY2000RRNIH
New York University School Of Medicine, New York NY
Investigators
Linked publications & trials
Paper 38712163Paper 32400971Paper 32388509Paper 30689585Paper 28183528Paper 27036079Paper 27001614Paper 26827652Paper 26449541Paper 26366463Paper 26092349Paper 26079503Paper 26079416Paper 25778476Paper 25663231Paper 25572087Paper 25531812Paper 25199842Paper 25188341Paper 24925880Paper 24795354Paper 24736183Paper 24260125Paper 24244562Paper 24144899Paper 23944767Paper 23907679Paper 23673467Paper 23571587Paper 23565137Paper 23419804Paper 23360175Paper 23169101Paper 23143602Paper 23068916Paper 23055555Paper 23028556Paper 22869155Paper 22695340Paper 22685416Paper 22585765Paper 22505863Paper 22503001Paper 22294817Paper 22257000Paper 22020091Paper 22019225Paper 22019221Paper 21968671Paper 21966427Paper 21941167Paper 21900087Paper 21841246Paper 21786117Paper 21775922Paper 21742304Paper 21554737Paper 21532539Paper 21514691Paper 21460841Paper 21396623Paper 21391952Paper 21344056Paper 21339641Paper 21316814Paper 21293986Paper 21274294Paper 21233301Paper 21069334Paper 20939094Paper 20921898Paper 20878462Paper 20871389Paper 20847343Paper 20837357Paper 20827170Paper 20825306Paper 20817151Paper 20807066Paper 20697030Paper 20672447Paper 20662716Paper 20650002Paper 20622678Paper 20531015Paper 20524222Paper 20511180Paper 20504322Paper 20495438Paper 20467286Paper 20459885Paper 20436781Paper 20406333Paper 20400411Paper 20400410Paper 20399927Paper 20338687Paper 20309924Paper 20237308Paper 20235838
Abstract
This Phase II, randomized, study will evaluate the safety, plasma pharmacokinetics, and antiviral activity of T-20, a new class of antiretroviral agents, in HIV+ adults who have failed their current antiretroviral regimen. T-20 will be given by either continuous subcutaneous infusion or subcutaneous injection for 28 days.
View original record on NIH RePORTER →